Viking Therapeutics reported additional results this morning from its 12-week Phase 2 data of the lower 5mg dose of VK2809 in patients with non-alcoholic fatty liver disease. The "compelling" results show "impressive" safety and efficacy at low doses, H.C. Wainwright analyst Joseph Pantginis tells investors in a research note. Importantly, VK2809 at low doses is able to "significantly reduce" liver fat content in 12 weeks to an extent similar to the one demonstrated by the higher doses tested, says the analyst. He reiterates a Buy rating on Viking Therapeutics with a $31 price target.